(Q35180072)

7 August 2017

1 reference

title

Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy (English)

1 reference

7 August 2017

1 reference

metastatic breast cancer

1 reference

John Crown

1

1 reference

7 August 2017

Mark Pegram

series ordinal

2

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

Breast Cancer Research and Treatment

7 August 2017

1 reference

7 August 2017

79 Suppl 1

1 reference

7 August 2017

S11-8

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1024373306493

7 August 2017

0 references

cites work

Interaction between Herceptin and taxanes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

The platinum agents: a role in breast cancer treatment?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024373306493

7 January 2021

Identifiers

DOI

10.1023/A:1024373306493

1 reference

Dimensions Publication ID

7 August 2017

0 references

1 reference